STOCK TITAN
  1. Home
  2. Sec-filings
  3. CRBP
  4. [8-K] Corbus Pharmaceuticals Holdings, Inc. Reports Material Event

Corbus Pharmaceuticals (NASDAQ: CRBP) doubles Q2 loss while securing FDA clearance for Phase 3 trial

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Corbus Pharmaceuticals Holdings reported second-quarter 2026 results and corporate updates, highlighting progress in its oncology and obesity pipeline. The company obtained FDA clearance to proceed with TEMPO-1, a registrational Phase 3 study of CRB-701 in second-line oropharyngeal cancer, and plans to begin enrollment in September 2026. It also completed last patient last visit in the 240-patient CANYON-1 Phase 1b trial of CRB-913 in obesity, with topline data expected in September 2026, and strengthened leadership with a new Chief Medical Officer, Chief Business Officer and Board member.

For the quarter ended June 30, 2026, Corbus recorded a net loss of approximately $35.0 million, or $1.81 per basic and diluted share, compared with a net loss of approximately $17.7 million, or $1.44 per share, a year earlier. Operating expenses rose to approximately $36.2 million from $19.2 million, driven largely by increased clinical development spending, including a $10.0 million milestone payment under the CRB-701 license. Cash, cash equivalents and investments totaled $117.9 million as of June 30, 2026, which Corbus expects will fund operations into 2028 based on current plans.

Positive

  • FDA clearance to initiate the TEMPO-1 registrational Phase 3 study of CRB-701 in second-line oropharyngeal cancer advances the lead oncology program toward a potential approval pathway.
  • Cash, cash equivalents and investments of $117.9 million as of June 30, 2026 are expected to fund operations into 2028 based on current operating plans.

Negative

  • Net loss for Q2 2026 roughly doubled year-over-year to approximately $35.0 million as operating expenses increased sharply, including a $10.0 million development milestone under the CRB-701 license.

Filing Explained

The balance sheet reports 18,671,498 common shares issued and outstanding at June 30, 2026, versus 17,611,511 at December 31, 2025, establishing a larger disclosed share base for existing holders.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Net loss Q2 2026 approximately $35.0 million Three months ended June 30, 2026
Net loss Q2 2025 approximately $17.7 million Three months ended June 30, 2025
Operating expenses Q2 2026 approximately $36.2 million Three months ended June 30, 2026
Operating expenses Q2 2025 approximately $19.2 million Three months ended June 30, 2025
CRB-701 milestone payment $10.0 million Development milestone under CRB-701 licensing agreement in Q2 2026 operating expenses
Cash, cash equivalents and investments $117.9 million Balance on hand as of June 30, 2026, expected to fund operations into 2028
Net loss per share Q2 2026 $1.81 Net loss per basic and diluted share for the three months ended June 30, 2026
Weighted average shares Q2 2026 19,407,688 Weighted average number of common shares outstanding, basic and diluted, for Q2 2026
registrational study regulatory
"Obtained FDA clearance to proceed with registrational study (TEMPO-1) of CRB-701"
A registrational study is a late-stage clinical trial designed to give the government regulators the evidence they need to decide whether a drug, therapy, or medical device can be approved for sale. Think of it as the final exam or road test for a medical product: its results largely determine whether the product can reach the market, which directly affects potential revenue, company valuation, and investor risk.
Fast Track designations regulatory
"The U.S. Food and Drug Administration (FDA) has granted Fast Track designations to CRB-701"
A fast track designation is a regulatory status granted to a drug or therapy intended to treat a serious condition with unmet medical need, which gives the developer access to expedited interactions and review procedures with regulators. For investors, it’s like an express lane: it can shorten development and review timelines and reduce regulatory uncertainty, potentially speeding a product to market—but it does not guarantee approval or commercial success.
antibody drug conjugate medical
"CRB-701 is a next-generation, highly stable Nectin-4 targeting antibody drug conjugate (ADC)"
An antibody drug conjugate is a targeted medical treatment that combines a special antibody with a powerful drug, allowing precise delivery of the medicine directly to cancer cells or other harmful cells in the body. For investors, it represents a sophisticated approach to therapy that could improve treatment effectiveness and reduce side effects, potentially leading to significant growth opportunities in the biotech and pharmaceutical sectors.
CB1 inverse agonist medical
"CRB-913 is a highly peripherally restricted oral CB1 inverse agonist for the treatment of obesity"
A CB1 inverse agonist is a drug that binds to the brain and nervous system’s CB1 cannabinoid receptor and pushes its activity below its normal resting level, producing effects opposite to those of cannabis-like stimulation. For investors, these drugs matter because altering appetite, mood, pain or addiction pathways can create significant market opportunities or regulatory risks—think of it as turning a dimmer switch lower than the factory setting to achieve a different therapeutic outcome.
second-line (2L) medical
"registrational study (TEMPO-1) of CRB-701 in 2L oropharyngeal cancer"
Phase 1b clinical trial medical
"CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity"
A phase 1b clinical trial is an early-stage human study that follows initial safety tests and checks how a new drug or treatment works at different doses in the target patient group. It matters to investors because it is one of the first steps showing whether a therapy is tolerable and shows any sign of benefit in real patients — like a small proof-of-concept test that can significantly raise or lower a drug’s commercial prospects.
Net loss approximately $35.0 million
Net loss per share (basic and diluted) $1.81
Operating expenses approximately $36.2 million
Cash, cash equivalents and investments $117.9 million

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What were Corbus Pharmaceuticals (CRBP) key financial results for Q2 2026?
Corbus reported a net loss of approximately $35.0 million, or $1.81 per basic and diluted share, for Q2 2026. This compares with a net loss of about $17.7 million, or $1.44 per share, for the same quarter in 2025.

How much cash runway does Corbus Pharmaceuticals (CRBP) report as of June 30, 2026?
As of June 30, 2026, Corbus held $117.9 million in cash, cash equivalents and investments. The company states this balance is expected to fund operations into 2028 based on its current operating plans and planned expenditures.

What are the main upcoming clinical milestones for Corbus Pharmaceuticals (CRBP)?
Corbus plans to begin enrollment in the TEMPO-1 Phase 3 study of CRB-701 in September 2026 and report topline CANYON-1 Phase 1b obesity data for CRB-913 in September 2026, with CRB-701 plus Keytruda data expected in Q1 2027.

What is CRB-701 and what regulatory status has it received at Corbus (CRBP)?
CRB-701 is a Nectin-4 targeting antibody drug conjugate for oropharyngeal and cervical cancers. It has received Fast Track designations from the FDA for both tumor types and recently obtained FDA clearance to proceed with the TEMPO-1 registrational study.

What is CRB-913 and what is the status of the CANYON-1 trial at Corbus (CRBP)?
CRB-913 is an oral, highly peripherally restricted CB1 inverse agonist being developed for obesity. Corbus has completed last patient last visit in the 240-patient CANYON-1 Phase 1b trial and expects to report topline data in September 2026.

What leadership changes did Corbus Pharmaceuticals (CRBP) announce for Q2 2026?
Corbus appointed Leonardo Viana Nicacio, M.D. as Chief Medical Officer, Nishant Saxena as Chief Business Officer, and Brent Pfeiffenberger to its Board of Directors, adding experience in oncology development, corporate finance, and commercial operations.
false000159509700015950972026-08-062026-08-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 6, 2026

CORBUS PHARMACEUTICALS HOLDINGS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-37348

46-4348039

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

500 River Ridge Drive

Norwood, Massachusetts

02062

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 963-0100

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

Trading
Symbol(s)


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

CRBP

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 2.02 Results of Operations and Financial Condition.

Corbus Pharmaceuticals Holdings, Inc. (the “Company”) issued a press release on August 6, 2026, disclosing financial information and operating metrics for its fiscal quarter ended June 30, 2026, and discussing its business outlook. A copy of the Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

See “Item 2.02 Results of Operations and Financial Condition” above.

The information in this Current Report on Form 8-K under Items 2.02 and 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by a specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) The following exhibit is furnished with this report:

Exhibit No.

Description

99.1

Press Release issued by Corbus Pharmaceuticals Holdings, Inc. dated August 6, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Corbus Pharmaceuticals Holdings, Inc.

Date:

August 6, 2026

By:

/s/ Yuval Cohen

Name: Yuval Cohen
Title: Chief Executive Officer

 

 

 

Exhibit 99.1

Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update

•
Obtained FDA clearance to proceed with registrational study (TEMPO-1) of CRB-701 in 2L oropharyngeal cancer and expect to initiate enrollment in September 2026
•
Concluded last patient last visit in CANYON-1 Phase 1b study (n=240) of CRB-913 in obesity and on track to report data in September 2026
•
Appointed new Chief Medical Officer, Chief Business Officer, and Board Member to strengthen senior leadership and guide the Company through registrational studies and commercialization readiness

 

Norwood, MA, August 6, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing new therapies in oncology and obesity, today provided a corporate update and reported financial results for the 2026 second quarter ended June 30, 2026.

"We’ve continued to build momentum as we prepare for two potentially impactful clinical development milestones in September: commencing enrollment of TEMPO-1, our Phase 3 study of CRB-701 in oropharyngeal cancer, and the data readout of CANYON-1, our Phase 1b study of CRB-913 in obesity. Both programs represent opportunities to address areas of significant unmet medical need,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “CRB-701 has the potential to bring a much-needed therapeutic option for the growing oropharyngeal cancer patient population, for whom approved and other investigational therapies have shown little promise. CRB-913 is a unique daily oral obesity drug candidate with a mechanism of action entirely orthogonal to the GLP-1 class and with the potential for both weight loss and long-term weight management. We look forward to a productive second half of 2026 as we work to improve patient outcomes and generate meaningful value for shareholders.”

Key Corporate and Program Updates

 

CRB-701 is a next-generation, highly stable Nectin-4 targeting antibody drug conjugate (ADC) being developed to treat oropharyngeal squamous cell carcinoma (OPSCC), a type of head and neck squamous cell carcinoma (HNSCC), as well as cervical cancer. The U.S. Food and Drug Administration (FDA) has granted Fast Track designations to CRB-701 for the treatment of both cancer types. CRB-701 is licensed from CSPC Megalith Biopharmaceutical Co. Ltd. China.

 

•
Obtained FDA clearance to proceed with TEMPO-1 registrational study (n=250) of CRB-701 in 2L OPSCC, representing the first registrational trial specifically designed to evaluate a targeted treatment in this patient population.
•
Expect to commence enrollment in the TEMPO-1 study in September 2026.
•
Reported 2L+ monotherapy data from the Phase 1/2 study of CRB-701 in HNSCC and cervical cancers at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Link here for press release with more details (https://ir.corbuspharma.com/news-events/press-
releases/detail/471/corbus-pharmaceuticals-reports-updated-crb-701-phase-12-clinical-data-demonstrating-robust-activity-in-2l-oropharyngeal-and-cervical-cancers).
•
Anticipate reporting CRB-701 + Keytruda® combination data in first-line (1L) settings in OPSCC patients in Q1 2027 to support potential further registration-enabling trials in the front line.

 

CRB-913 is a highly peripherally restricted oral CB1 inverse agonist for the treatment of obesity.

 

•
Concluded last patient last visit in the CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity. The CANYON-1 study followed 240 patients over a 12-week treatment period followed by a 4-week safety follow-up.
•
On track to report topline data from CANYON-1 Phase 1b study in September 2026.

 

Corporate Appointments

 

Corbus strengthened its leadership team and Board of Directors with several key appointments in the second quarter of 2026.

 

•
Leonardo Viana Nicacio, M.D. as Chief Medical Officer. Dr. Nicacio previously served as Chief Medical Officer at Protara Therapeutics and Senior Vice President, Head of Clinical Development and Global Medical Affairs at Stemline Therapeutics. He also held roles of increasing responsibility at Seagen (acquired by Pfizer), most recently as Vice President of Clinical Development, overseeing programs across a range of cancers, including bladder, breast, gynecologic, lung, colorectal, and head and neck cancers, and most notably the development of a therapeutic for metastatic cervical cancer, TIVDAK®.
•
Nishant Saxena as Chief Business Officer. Mr. Saxena most recently served as Chief Financial Officer at Jeune Aesthetics, Inc., a wholly owned subsidiary of Krystal Biotech, Inc. Previously, he served as a Managing Director in Evercore’s healthcare group, where he advised on transactions totaling over $500 billion in aggregate value. Earlier in his career, Mr. Saxena held positions of increasing responsibility in private equity, venture capital, and investment advisory firms.
•
Brent Pfeiffenberger to Board of Directors. Dr. Pfeiffenberger is currently President and Chief Executive Officer of Century Therapeutics and the Chair of its Board of Directors. Previously, Dr. Pfeiffenberger served as Chief Operating Officer of Neogene Therapeutics (acquired by AstraZeneca). Prior to Neogene, he spent nearly two decades in leadership roles of increasing responsibility at Bristol Myers Squibb, most recently as Senior Vice President, Head of U.S. Oncology, where he oversaw business operations for the multi-billion-dollar franchise.

 

Financial Results for the Quarter Ended June 30, 2026

The Company reported a net loss of approximately $35.0 million, or a net loss per basic and diluted share of $1.81, for the three months ended June 30, 2026, compared to a net loss of approximately $17.7 million, or a net loss per basic and diluted share of $1.44, for the three months ended June 30, 2025.

Operating expenses increased by $17.0 million to approximately $36.2 million for the three months ended June 30, 2026, compared to approximately $19.2 million for the three months ended June 30, 2025. The increase was primarily attributable to an increase in clinical development expenses, which includes a $10.0 million development milestone payment pursuant to the licensing agreement for CRB-701.

The Company had $117.9 million of cash, cash equivalents, and investments on hand as of June 30, 2026, which is expected to fund operations into 2028 based on current operating plans and planned expenditures.

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on developing new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate for the treatment of Nectin-4-expressing tumors and CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act of 1995, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, anticipated regulatory interactions and outcomes, including alignment with FDA on trial design, potential accelerated approval market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities, sufficiency of cash runway and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission including those described in our Annual Report on Form 10-K for the year ended December 31, 2025, and other filings we make with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company

undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.

 

INVESTOR CONTACTS:

Sean Moran

Chief Financial Officer

Corbus Pharmaceuticals

smoran@corbuspharma.com

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

 

MEDIA CONTACT:

Liz Melone

Founder & Principal

Melone Communications, LLC

liz@melonecomm.com

 

---tables to follow---

Corbus Pharmaceuticals Holdings, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

(Unaudited)

 

 

 

 

For the Three Months
Ended June 30,

 

 

For the Six Months Ended
June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

31,175

 

 

$

15,187

 

 

$

50,994

 

 

$

30,829

 

General and administrative

 

 

5,015

 

 

 

3,965

 

 

 

9,500

 

 

 

8,098

 

Total operating expenses

 

 

36,190

 

 

 

19,152

 

 

 

60,494

 

 

 

38,927

 

Operating loss

 

 

(36,190

)

 

 

(19,152

)

 

 

(60,494

)

 

 

(38,927

)

Other income (expense), net:

 

 

 

 

 

 

 

 

 

 

 

 

Interest and investment income, net

 

 

1,164

 

 

 

1,314

 

 

 

2,566

 

 

 

2,995

 

Other (expense) income, net

 

 

(11

)

 

 

176

 

 

 

(78

)

 

 

1,292

 

Total other income, net

 

 

1,153

 

 

 

1,490

 

 

 

2,488

 

 

 

4,287

 

Net loss

 

$

(35,037

)

 

$

(17,662

)

 

$

(58,006

)

 

$

(34,640

)

Net loss per share, basic and diluted

 

$

(1.81

)

 

$

(1.44

)

 

$

(3.04

)

 

$

(2.83

)

Weighted average number of common shares outstanding, basic and diluted

 

 

19,407,688

 

 

 

12,240,443

 

 

 

19,059,092

 

 

 

12,221,373

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(35,037

)

 

$

(17,662

)

 

$

(58,006

)

 

$

(34,640

)

Other comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

Change in unrealized gain (loss) on marketable debt securities

 

 

54

 

 

 

(16

)

 

 

(54

)

 

 

(74

)

Total other comprehensive income (loss)

 

 

54

 

 

 

(16

)

 

 

(54

)

 

 

(74

)

Total comprehensive loss

 

$

(34,983

)

 

$

(17,678

)

 

$

(58,060

)

 

$

(34,714

)

 

 

 

Corbus Pharmaceuticals Holdings, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

 

 

 

 

June 30, 2026

(unaudited)

 

 

December 31, 2025

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

23,370

 

 

$

28,492

 

Investments

 

 

94,571

 

 

 

134,777

 

Restricted cash

 

 

—

 

 

 

670

 

Prepaid expenses and other current assets

 

 

4,812

 

 

 

3,015

 

Total current assets

 

 

122,753

 

 

 

166,954

 

Restricted cash

 

 

385

 

 

 

—

 

Property and equipment, net

 

 

71

 

 

 

159

 

Operating lease right-of-use assets

 

 

3,779

 

 

 

1,082

 

Total assets

 

$

126,988

 

 

$

168,195

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

5,254

 

 

$

2,215

 

Accrued expenses

 

 

15,230

 

 

 

16,844

 

Operating lease liabilities

 

 

999

 

 

 

1,633

 

Total current liabilities

 

 

21,483

 

 

 

20,692

 

Operating lease liabilities, noncurrent

 

 

3,265

 

 

 

—

 

Total liabilities

 

 

24,748

 

 

 

20,692

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at June 30, 2026 and December 31, 2025

 

 

—

 

 

 

—

 

Common stock, $0.0001 par value; 300,000,000 shares authorized,
18,671,498 and 17,611,511 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively

 

 

2

 

 

 

2

 

Additional paid-in capital

 

 

715,781

 

 

 

702,984

 

Accumulated deficit

 

 

(613,436

)

 

 

(555,430

)

Accumulated other comprehensive loss

 

 

(107

)

 

 

(53

)

Total stockholders’ equity

 

 

102,240

 

 

 

147,503

 

Total liabilities and stockholders’ equity

 

$

126,988

 

 

$

168,195

 

 

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

2 documents

Press Releases

Other Documents